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Background: EORTC 24971 was a phase III trial demonstrating superiority of 
induction regimen TPF over PF, in terms of progression-free (PFS) and overall 
survival (OS) in locoregionally advanced unresectable HNSCC. We conducted a 
retrospective analysis of prospectively collected data aiming to evaluate whether only 
HPV(−) patients (pts) benefit from adding docetaxel to PF, in which case de-
intensifying induction treatment in HPV(+) pts could be considered. 
Methods: Pre-therapy tumor biopsies (blocks or slides) were assessed for high-risk 
HPV by p16 immunohistochemistry, PCR and qPCR. HPV-DNA+ and/or p16+ tumors 
were subjected to in situ hybridization (ISH) and HPV E6 oncogene expression qRT-
PCR analysis. Primary and secondary objectives were to evaluate the value of 
HPV/p16 status as predictive factor of treatment benefit in terms of PFS and OS. The 
predictive effect was analyzed based on the model used in the primary analysis of 
the study with the addition of a treatment by marker interaction term and tested at 
two-sided 5% significance level. 
Results: 119 of 358 pts had available tumor samples and 58 of them had 
oropharyngeal cancer. Median follow-up was 8.7 years. Sixteen of 119 (14%) 
evaluable samples were p16+ and 20 of 79 (25%) evaluable tumors were HPV-
DNA+. 13 of 40 pts (33%) assessed with HPV-DNA ISH and 12 of 28 pts (43%) 
assessed for HPV E6 mRNA were positive. The pre-planned analysis showed no 
statistical evidence of predictive value of HPV/p16 status for PFS (p=0.287) or OS 
(p=0.118). 
Conclusions: The incidence of HPV positivity was low in the subset of EORTC 
24971 pts analyzed. In this analysis only powered to detect a large treatment by 
marker interaction there was no statistical evidence that treatment effect found 
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overall was different in magnitude in HPV(+) or HPV(−) pts. These results do not 
justify selection of TPF versus PF according to HPV status. 
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Head and Neck Squamous Cell Carcinomas (HNSCC) is expected to account 
for approximately 740,000 new cases and 410,000 deaths worldwide, for the year 
2015 [1]. In Europe, HNSCC incidence and mortality rates are higher compared to 
the United States, with approximately 140,000 new cases diagnosed in 2014, 
corresponding to an annual incidence of 43/100,000 [2]. Tobacco and alcohol use 
account for the vast majority of HNSCC.  Human papillomavirus (HPV) infection has 
been more recently identified as the cause of a distinct subset of HNSCC that arise 
primarily in the oropharynx [3]. In particular, HPV16 is responsible for more than 90% 
of HPV positive (HPV(+)) OPSCC [4]. 
Accumulating evidence clearly suggests that HPV-associated OPSCC 
represent a distinct entity in terms of epidemiology, biology and clinical behavior. 
Multiple methods for determination of HPV status are available. HPV DNA detection 
in tumors per se cannot prove causal association as HPV is ubiquitously present in 
humans. HPV DNA PCR is a sensitive but not specific method for determination of 
HPV status. Immunohistochemistry (IHC) for p16 protein expression is used as a 
surrogate marker of HPV infection in OPSCC. A negative autoregulatory loop 
between p16 and pRb has been described [5] and degradation of pRb by HPV E7 
oncoproteins leads to p16 upregulation in HPV positive cancers. p16 IHC followed by 
PCR for HPV DNA has been proposed as a reliable algorithm for detection of HPV in 
paraffin embedded OPSCC specimens. p16 protein expression, however,  is not a 
reliable surrogate marker for HPV infection outside the oropharynx. HPV DNA in situ 
hybridization (ISH) can differentiate between integrated and episomal forms of HPV 
in tumors but lacks sensitivity. The gold standard is detection of E6/E7 mRNA, but 
this may be less sensitive depending on the quality of the clinical sample. In addition, 
many HPV(+) patients identified in the next generation sequencing study by Parfenov 
et al.  had low expression or absence of E6/E7 expression and could be misclassified 
by E6/E7 mRNA detection [6].  
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HPV(+) OPSCC has a significantly better prognosis independent of stage at 
diagnosis compared to their HPV(−) counterpart [7]. The risk of death for HPV(+) 
patients is consistently less than 60% that of HPV(−) cancers across studies and the 
absolute survival difference is consistently higher than 30%. Deintensification 
research strategies that aim to reduce treatment-related morbidity and improve 
patient quality of life without compromising treatment effectiveness are being tested 
in clinical trials. Patients with HPV(+) OPSCC are young and expected to live long, 
therefore, morbidity resulting from late toxicity is a concern in these patients. To that 
extent, in the present study our aim was to evaluate whether only HPV(−) patients 
derive benefit from adding docetaxel to PF, in which case deintensifying induction 
treatment in HPV(+) patients could be considered. 
This project was approved by the EORTC Translational Research Advisory 
Committee (TRAC) in May 2010. 
 
MATERIALS AND METHODS 
Subjects and Collection of biological material 
EORTC 24971 randomized 358 patients with primary inoperable non 
metastatic HNSCC between TPF (docetaxel, cisplatin, 5-fluorouracil) chemotherapy 
and PF (cisplatin/5-fluorouracil) induction chemotherapy followed by radiotherapy 
and demonstrated statistically significant improvements in progression free survival 
(PFS) and overall survival (OS) with the addition of docetaxel to PF [8]. Samples 
have been collected in the frame of the EORTC 24971 study from 1999 until 2002. 
The two main challenges to conduct the retrospective translational research 
(TR) study were: (1) to get a clear view on the available material – as the research 
was not planned at the time of the protocol; (2) to get Ethical Committees approval 
for this research while the patient information sheet/inform consent did not mention 
any kind of biological material collection (in the frame of planned nor 
unplanned/future research).  
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In order to solve the first point, feasibility was conducted among the 
participating sites, from 2009 until 2011. In 2011, 14 sites answered positively to the 
request (corresponding to 209 patients) and 5 sites answered negatively (e.g. tissue 
samples not available anymore). Regarding the second point, most of the ECs did 
not have any specific requests (patient reconsent, etc). In France, the initial EC 
feedback required a declaration of biological collection, with abstention of ministerial 
approvals and patients reconsent/special derogation for deceased patients. Finally, 
the collection was possible as the EC agreed to the collection for deceased or lost in 
follow-up patients, without derogations and without ministerial approvals. In total, 4 
years were dedicated to the operational part of setting-up this translational research 
project, covering the feasibility, the EC submission and approval processes, and the 
sample shipment.  
We managed to collect 119 HNSCC tissue samples which were assessed for 
high risk HPV infection by p16 IHC, PCR and quantitative PCR (qPCR). HPV DNA+ 
and/or p16+ tumors were subjected to ISH and HPV E6 oncogene expression 
analysis by qRT-PCR. 
 
Assays 
Immunohistochemical (IHC) staining for p16 
IHC was performed to determine p16 expression using a p16 mouse 
monoclonal antibody (predilute, mtm-CINtech, E6H4) as previously described [9]. 
p16 was considered to be positive when defined as strong and diffuse nuclear and 
cytoplasmic staining in ≥70% of the tumor cells, which is the same scoring criteria 
used by Ang et al. [9]. 
 
DNA extraction from paraffin sections 
Two 10 µm-paraffin sections from HNSCC specimens were used for DNA 
extraction by the QIAamp DNA FFPE Tissue kit (QIAGEN, Germany), according to 
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manufacturer’s instructions. The DNA was eluted in QIAGEN ATE buffer and stored 
at -20oC until analysis. 
 
Detection of high-risk HPV DNA by PCR 
For high-risk HPV DNA detection, the two most popular worldwide consensus 
PCR reactions were used: the MY system [10] and the GP+ system [11] both 
amplifying regions of L1 HPV gene. DNA integrity was assessed by PCR 
amplification of β-globin with PC04 and GH020 primers [10]. PCR reactions were 
performed in the GENEAmp PCR System 9600 (Applied Biosystems, USA). The 
protocols for the PCR detection of high-risk HPV DNA are provided in supplementary 
information (SI) text. 
 
HPV RFLP typing  
In case of a positive sample in the MY and/or GP+ PCR system, reactions 
were performed again in quadruplicate, mixed and their product was subjected to 
restriction fragment polymorphism analysis using the BamHI, DdeI, HaeIII, HinfI, PstI 
and RsaI restriction enzymes (New England Biolabs, USA). Analysis performed in 
2% Nusieve 1:1 agarose gel as previously reported [12]. Assignment of an HPV type 
to a particular risk category was done according to Munoz et al. [13]. The protocols 
for HPV RGLP typing are provided in SI text. 
 
Real time qPCR for detection of HPV16, 18 and 31 
In case of negative samples in MY PCR system, novel real-time qPCR 
assays were developed in order to provide a more sensitive detection for those HPV 
types most commonly found in oropharyngeal cancers; types HPV16, 18 and 31. The 
qPCR primers used amplify a 93bp HPV16 E6 region [14], a 185bp HPV18 E1 region 
[15] and a 350bp HPV31 E6 region (in-house assay). The protocols for real-time 




RNA extraction from hematoxylin and eosin stained slides 
RNA was extracted from hematoxylin and eosin stained slides using High 
Pure FFPET RNA Isolation Kit (ROCHE, Germany), according to manufacturer’s 




cDNA synthesis was performed using the SuperScript™ First-Strand 
Synthesis System for RT-PCR (Life technologies, USA) according to manufacturer’s 
protocol. Additional information for cDNA synthesis is provided in SI text. 
 
HPV in situ hybridization 
High-risk HPV status was determined by ISH using a cocktail probe that 
detects HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66 (GenPoint HPV 
probe cocktail; Dako, Carpinteria, CA). HPV ISH was interpreted as positive when 
nuclear-specific staining was detected in the tumor cells. The protocols for HPV ISH 
are provided in SI text. 
 
Detection of HPV E6 mRNA on paraffin embedded tissue 
Novel SYBR Green-based qPCR assays were developed for the detection of 
E6 mRNA expression of HPV16, 18 and 31 on FFPE samples. The specific qPCR 
primers used give rise to a 109bp HPV16-specific and a 131bp HPV18-specific 
amplicons, as previously described [16, 17]. Novel specific primers for HPV31 E6 
gene expression were designed giving rise to a 165bp specific amplicon. GAPDH 
and β-actin were used as our assays endogenous reference genes. The protocols for 






PFS and OS curves by treatment and marker strata were produced using the 
Kaplan-Meier method. PFS and OS were based on the long-term survival analysis 
produced in 2011 [18]. Statistical significance of predictive effects was assessed 
based on the model used in the primary analysis of the study with the addition of a 
treatment by marker interaction term. This was a multivariate Cox proportional 
hazards model with treatment, marker and treatment by marker interaction effects, 
adjusted for the following covariates: location of primary tumor (oral cavity, 
oropharynx, or hypopharynx), clinical tumor stage (T), regional-node stage (N), and 
WHO score for performance status. For the two initially planned analyses, the 
treatment by marker interaction was tested at a two-sided 5% significance level. The 
estimate of the hazard ratio HR for treatment in each marker strata was provided with 
its 95% confidence interval. For the additional analyses (22 statistical tests), the 
Benjamini-Hochberg method was applied to control the False Discovery Rate (FDR). 




A total 119 tissue samples were obtained from 119 of the 358 patients 
included in EORTC 24971 study and assessed for p16/HPV markers. Eighty two 
samples were FFPE blocks and 37 were FFPE slides; Median follow-up for these 
119 patients was 8.7 years. The baseline characteristics of these patients are shown 
in supplementary table S1. Patients selected for this project did not differ significantly 
from the rest of patients with respect to age, gender, tumor site, T stage, nodal stage, 
although baseline performance status was better, as assessed by t-test for age and 
from Fisher’s exact test for binary or categorical variables. Kaplan-Meier curves of 





One hundred nineteen specimens were evaluable for p16 by 
immunohistochemistry. Sixteen of the 119 patients were positive for p16:  The 
incidence of p16 positivity in the cohort was 13.4% (95% CI: 7.9%-20.9%). The 
distribution of p16 positivity by tumor site is shown in Table 1. 
 
Detection of high-risk HPV DNA by PCR 
Seventy nine of 82 FFPE were evaluable for HPV DNA by PCR. All samples 
were subject to histopathological evaluation, DNA quality control, and HPV DNA 
detection. Twenty of 79 FFPE (25.3%, 95% CI: 16.2%-36.4%) specimens were 
positive for high-risk HPV DNA (Table 1). Of the 20 HPV(+) FFPEs samples, 8 
contained HPV16, one HPV18, 7 HPV31 and 3 had infection with both HPV16 and 
HPV31, while one was unspecified. Ten of 20 HPV DNA+ FFPEs by PCR were also 
p16+. The distributions of HPV DNA by p16 status and of p16/HPV DNA positive 
samples by tumor site are provided in supplementary tables S2 and S3, respectively. 
 
HPV in situ hybridization 
HPV ISH using a set of probes for high-risk HPV detection was performed 
both in cases that had slides instead of FFPEs as well as in cases with positive 
status for either p16 or HPV DNA by PCR. Forty one samples met these criteria and 
13 of those were HPV(+) by ISH (32.5%, 95% CI: 18.6%-49.1%) (Table 1).  
 
Detection of HPV E6 mRNA on FFPE 
HPV DNA+ and/or p16+ tumors were subjected to HPV E6 oncogene 
expression analysis by qRT-PCR. Twenty eight samples were evaluable for high-risk 
HPV RNA analysis by qRT-PCR and 12 of them (11 for HPV16 and 1 for HPV18) 




Predictive effect of HPV status  
The pre-planned analysis showed no statistical evidence of predictive value of 
p16/HPV DNA by PCR status for PFS (p=0.287) or OS (p=0.118). Kaplan-Meier 
curves are shown in Figure 1. 
The additional analyses, adjusted for multiplicity to control FDR, showed no 
statistical evidence of a prognostic or predictive effect; on PFS or OS; based on 
either markers; in all tumors or restricted to oropharynx.  
 
DISCUSSION 
In the present study we sought to evaluate whether only HPV(−) patients 
derive benefit from adding docetaxel to PF in induction chemotherapy, in which case 
deintensifying induction treatment in HPV(+) patients could be considered. We 
analyzed pretreatment specimens from patients enrolled in EORTC 24971, a phase 
III study demonstrating superiority of induction regimen TPF over PF in terms of 
progression-free (PFS) and overall survival (OS) in locoregionally advanced 
unresectable HNSCC [8], for HPV status. The magnitude of the treatment effect 
found overall was not statistically different in p16/HPV positive or negative patients. 
However, this was a prospective - retrospective analysis only powered to detect a 
large treatment by marker interaction.  
Our primary and secondary objectives were to evaluate the value of HPV/p16 
status as predictive factor of treatment benefit in terms of PFS and OS, respectively. 
The study was designed in 2008 and at that time p16 immunohistochemistry followed 
by HPV DNA PCR in p16 positive cases had been demonstrated to be a reliable 
algorithm for a biologically and clinically relevant HPV infection in OPSCC. We 
therefore presumed that the same algorithm could be used for HPV detection in non-
OPSCC. However, it was subsequently shown that p16 protein expression is not a 
reliable surrogate marker for HPV infection outside the oropharynx [19]. Our study 
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population consisted of both OPSCC and non-OPSCC. We therefore performed HPV 
ISH and HPV E6 expression analysis in HPV DNA+ and/or p16+ cases. We found 
that the incidence of HPV was low in our EORTC 24971 cohort. The study was 
conducted between April 1999 and March 2002 and our findings are consistent with 
other studies examining the incidence of HPV infection in European populations 
during the same time period [20-23].  
We found that 8 of 20 HPV DNA+ FFPEs contained HPV16, one HPV18, 7 
HPV31, 3 had infection with both HPV16 and HPV31 and one was unspecified. Of 
the 28 HPV DNA+ and/or p16+ samples analyzed, expression of E6 oncogene 
detected in 12 samples, of which 11 samples were positive for HPV16 E6 and 1 
sample positive for HPV18 E6 expression. In the study by Bratman et al. [24], the 
presence of HPV was determined for 515 HNSCCs from TCGA. Seventy-three 
tumors contained HPV transcripts, among which 61 (84%) were HPV16, and 12 
(16%) were HPV-other (8 HPV33, 3 HPV35, and 1 HPV56). The authors reported 
that HNSCCs harboring HPV genotypes other than HPV16 have inferior survival. 
However, p16 status was not available for all cases with HPV-other genotypes; a 
prospective study of HPV-other genotype in OPSCC, uniformly characterized with 
p16 staining and tobacco history, and uniformly treated, is required before concluding 
that HPV-other genotypes confer poor prognosis in HNSCC. 
In addition to oropharynx, the subsite for which HPV carcinogenesis is best 
understood, our study also included oral cavity, larynx and hypopharynx. In the study 
of 3680 cases of HNSCC by Castellsagué et al. [25] the incidence of HPV positivity 
was 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, oral cavity, and larynx, 
respectively. HPV16 was the dominant genotype. In our study the incidence of 
HPV/p16 double positive was 6/10, 1/22, 1/7 and 2/32 in oropharynx, oral cavity, 
larynx and hypopharynx respectively. 
Our retrospective study was only powered to detect a large treatment by 
marker interaction. The study data did not show any evidence that HPV(+) or HPV(−)  
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patients benefit more from the addition of docetaxel to PF. Similar conclusion was 
reached  with the HPV analysis of TAX324 study, a phase III study comparing TPF to 
PF in patients with locoregionally advanced HNSCC treated with sequential therapy 
[26]. In this unplanned analysis of survival involving 111 patients, the authors 
reported no statistical differences between TPF and PF in HPV positive and HPV 
negative patients and that was attributed to the small numbers of patients and 
concomitant loss of statistical power. 
In conclusion, our study found that the incidence of HPV positivity in a subset 
of patients enrolled in EORTC 24971 was low. In this prospective-retrospective 
analysis only powered to detect a large treatment by marker interaction there was no 
statistical evidence that treatment effect found overall was different in magnitude in 
HPV(+) or HPV(−) negative patients. These results do not justify selection of TPF 
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Figure 1. Kaplan-Meier curves for PFS and OS for the subset of patients included in 
this project, by treatment arm (A, B) and by by treatment arm and p16 / HPV DNA by 
PCR status (C, D). 
Table 1: Distribution of p16/HPV by tumor site 
p16/HPV by tumor site 
 











 N (%) N (%) N (%) N (%) N (%) 
IHC for p16                                                                                                                                                                                                                                                                                                                    
 negative                                         19 (86.4)                                                                                           49 (84.5)                          29 (90.6)                                                               6 (85.7)    103 (86.6)                                                  
 positive                                           3 (13.6)                                                                                            9 (15.5)                          3 (9.4)                                      1 (14.3)                                                                             16 (13.4)                         
PCR for HPV DNA
1
                                                                                                                                                                                                                                                                                                                
 negative                                          7 (31.8)                                                                                         27 (46.6)                                            19 (59.4)                          6 (85.7)                59 (49.6)                                                                                      
 positive                                           1 (4.5)                                                                                          13 (22.4)                                        5 (15.6)                                 1 (14.3)                                                  20 (16.8)                                        
 non evaluable                                     1 (4.5)                                                                                             2 (3.4)                          0 (0.0)                                                                0 (0.0)                                                   3 (2.5)                           
 not done                                         13 (59.1)                                                                                           16 (27.6)                          8 (25.0)                                  0 (0.0) 37 (31.1)                                                              
HPV subtypes  
(only for HPV DNA positive samples) 
                                                                                                                                                                                                                                                                             
 unspecified                                       0 (0.0)                                                                                             0 (0.0) 1 (3.1)                                                                                         0 (0.0)                           1 (0.8)                                                                    
 type 16                                            0 (0.0)                                                                                             6 (10.3)                          2 (6.3)                                                                0 (0.0)                         8 (6.7)                                                                             
 type 18                                            0 (0.0)                                                                                             1 (1.7)                          0 (0.0)                                       0 (0.0)                                                                            1 (0.8)                                
 type 31                                            1 (4.5)                                                                                             4 (6.9)                          2 (6.3)                                                                0 (0.0)                                                   7 (5.9)                             
 type 16 combined with type 31                     0 (0.0)                                                                                             2 (3.4)                          0 (0.0)                                                                1 (14.3)                           3 (2.5)                                                                           
 missing                                          21 (95.5)                                                                                           45 (77.6)                          27 (84.4)                                      6 (85.7)                                                  99 (83.2)                                        
ISH for HPV DNA
2
                                                                                                                                                                                                                                                                                                               
 HPV DNA ISH negative                              2 (9.1)                                                                                          18 (31.0)              5 (15.6)                                                                                2 (28.6)                          27 (22.7)                         
 HPV DNA ISH positive                              4 (18.2)                                                                                            4 (6.9)                          3 (9.4)                                                               2 (28.6)                                                     13 (10.9)                         
 not evaluable / not done                       16 (72.7)                                                                                           36 (62.1)                          24 (75.0)                                      3 (42.9)                                                  79 (66.4)                                        
PCR for HPV RNA                                                                                                                                                                                                                                                                                                                
 HPV RNA PCR negative                           3 (13.6)                                                                                            8 (13.8)                          4 (12.5)                                                               1 (14.3)                          16 (13.4)                                                  
 HPV RNA PCR positive                           2 (9.1)                                                                                             8 (13.8)                          1 (3.1)                                       1 (14.3)                                                                            12 (10.1)                         
 not evaluable / not done
3
                         17 (77.3)                                                                                           42 (72.4)                          27 (84.4)                                                               5 (71.4)                                                  91 (76.5)                
HPV subtypes  
(only for HPV RNA positive samples) 
                                                                                                                                                                                                                                                                                                    
 type 16                                            2 (9.1)                                                   7 (12.1)                                                                    1 (3.1)                          1 (14.3)                                                               11 (9.2)                         
 type 18                                            0 (0.0)                                                                                             1 (1.7)                          0 (0.0)                                                                0 (0.0)                                                   1 (0.8)                           
 missing                                          20 (90.9)                                                                                           50 (86.2) 31 (96.9)                                                                                        6 (85.7)                                                                         107 (89.9)                               
1 
PCR for HPV DNA was assessed in 82 FFPE blocks
 
2
 HPV ISH was performed both in cases that had slides instead of FFPEs as well as in cases with positive 
status for either p16 or HPV DNA by PCR (40 samples) 
3




Figure 1. Kaplan-Meier curves for PFS and OS for the subset of patients included in this project, by 
treatment arm (A, B) and by by treatment arm and p16 / HPV DNA by PCR status (C, D).  
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MATERIALS AND METHODS 
Assays 
Detection of high-risk HPV DNA by PCR 
For high-risk HPV DNA detection, the two most popular worldwide consensus 
PCR reactions were used: the MY system [1] and the GP+ system [2] both amplifying 
regions of L1 HPV gene. DNA integrity was assessed by PCR amplification of β-
globin with PC04 and GH020 primers [1]. PCR reactions were performed in the 
GENEAmp PCR System 9600 (Applied Biosystems, USA).  
PCR reactions were performed in a 25 µl total reaction volume, containing 50-
100 ng genomic DNA, 2.5 µl of 10X PCR buffer (w/o MgCl2), 3 µl of 10 mM dNTPs 
mix, 0.75 µl of 50 mM MgCl2, 1.75 µl of 10 µΜ forward primer, 1.75 µl of 10 µΜ 
reverse primer and 0.25 µl of 5 U/µl Platinum Taq DNA polymerase (Invitrogen, Life 
Technologies). Amplification for β-globin was performed with the following cycling 
profile: incubation at 94 °C for 5 min followed by 36 cycles of 45 sec denaturation at 
94 °C, 45 sec annealing at 58 °C and 45 sec elongation at 72°C. The last cycle was 
followed by a final extension of 5 min at 72°C. Amplification for MY and GP+ systems  
was performed with the following cycling profile: incubation at 94 °C for 5 min 
followed by 40 cycles of 2 min denaturation at 94 °C, 2 min annealing at 55 °C for 
MY and 40oC for GP+ and 2 min elongation at 72°C. The last cycle was followed by a 
final extension of 5 min at 72°C. Appropriate controls including DEPC-H2O (blank 
reaction), DNA-negative for HPV and DNA-positive for HPV16 from SiHa cervical 
carcinoma cell line, were used. All necessary standard precautions were observed in 
order to avoid contamination through PCR carry-over. PCR products were analyzed 
in 1.5% w/v 1Χ TBE agarose gels.  
 
HPV RFLP typing  
In case of a positive sample in the MY and/or GP+ PCR system, reactions 
were performed again in quadruplicate, mixed and their product was subjected to 
restriction fragment polymorphism analysis: 13 µl of PCR product plus 1.5 µl 
restriction buffer NEB 2 and 0.5 µl of each of these restriction enzymes: BamHI, 
DdeI, HaeIII, HinfI, PstI and RsaI (New England Biolabs, USA) in separate tubes. 
Incubations lasted 4 h at 37°C and were analyzed subsequently in a 2% Nusieve 1:1 
agarose gel as previously reported [3]. Assignment of an HPV type to a particular risk 
category was done according to Munoz et al. [4]. 
 
Real time qPCR for detection of HPV16, 18 and 31 
In  case of  negative samples in the MY PCR system, novel real-time qPCR 
methods were developed in order to provide a more sensitive detection for those 
HPV types most commonly found in oropharyngeal cancers; types 16, 18 and 31. 
The primers for types 16 and 18 have been described elsewhere and amplify a 93bp 
for HPV16 E6 region and a 185bp for HPV18 E1 region, respectively [5, 6]. The 
following primers were synthesized in order to amplify a 350bp E6 region of HPV31 
type: HPV31F: 5’-TAAGCTCGGCATTGGAAATACCCT-3’ and HPV31R: 5’-
CCTTCCTCCTATGTTGTGGAATCG-3’. The assays for HPV16 and HPV18 were 
calibrated against the WHO international certified reference materials from NIBSC 
(UK) and they were able to easily detect a viral load of 5 IU/µl from each of the two 
types. The assay for HPV31 was calibrated against an in-house HPV31+ cervical 
carcinoma sample. 
The qPCR reactions were performed in glass capillaries in the LightCycler 
platform (Roche Applied Science) in a 10 µl total reaction volume, containing 50-100 
ng genomic DNA, 1 µl of 10X DNA Master SYBR Green I reagent (Roche Applied 
Science), 0.2 µl of 20 µΜ forward primer and 0.20 µl of 20 µΜ reverse primer. 
Amplification was initiated with an incubation at 94 °C for 5 min followed by 45 cycles 
of 10 sec denaturation at 95 °C, 30 sec annealing at 57 °C (for HPV16 at 60 °C) and 
40 sec elongation at 72°C. The last cycle was followed by melting curve analysis (10 
sec denaturation at 95 °C, 30 sec at 50 °C and up to 95°C at a 0.1 °C/sec rate with 
continuous monitoring of the F1 channel) for verification of the specificity of the 
reactions. The Tm of the amplicons was 79.07±0.48, 81.31±0.07 and 78.34±0.47 °C 
(average ± SD) for types 16, 18 and 31 respectively. 
 
cDNA synthesis 
cDNA synthesis was performed using the SuperScript™ First-Strand 
Synthesis System for RT-PCR (Life technologies, USA) according to manufacturer’s 
protocol. 7µl of isolated total RNA was used as starting template. Appropriate 
controls, DEPC-H2O (blank reaction) and positive for HPV16 RNA from SiHa cervical 
carcinoma cell line, were included. All necessary standard precautions were 
observed in order to avoid contamination through PCR carry-over. 
 
HPV in situ hybridization 
High-risk HPV status was determined by ISH using a cocktail probe that 
detects HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66 (GenPoint HPV 
probe cocktail; Dako, Carpinteria, CA). HPV ISH was interpreted as positive when 
nuclear-specific staining was detected in the tumor cells. In brief, sections after 
deparaffinization and rehydration, were pretreated with Target Retrieval solution for 
30 minutes, followed by background quenching with 0.3% H2O2 in methanol. Probe 
and target DNA denaturation was performed by heating at 92°C for 5 minutes and 
hybridization took place at 37°C overnight. Stringent wash step took place at 48°C for 
30 minutes. Detection of hybridized probe was performed by successive incubation 
of slides with Primary Streptavidin-HRP, followed by biotinyl tyramide and secondary 
Streptavidin-HRP solution. Finally sections were stained with DAB and 
counterstained with hematoxylin. Enzymatic reaction results in visible dark blue/black 
dots in the cell nuclei of positive cases. Cores from HPV16+ SiHa and HPV18+ HeLa 
cervical cancer cell lines fixed in formalin and embedded in paraffin were selected for 
positive controls. Evaluation of the HPV status was performed by two independent 
pathologists (N.G. and I.S.P.) under light microscopy.  
 
Detection of HPV E6 mRNA on paraffin embedded tissue 
Novel SYBR Green-based qPCR assays were developed and applied for the 
detection of E6 mRNA expression of HPV types 16, 18 and 31 on FFPE samples. 
Specific primers for HPV16 and HPV18 E6 genes were used as described previously 
in Shi et al. [7] (HPV16 E6 forward 5’-CAGTTATGCACAGAGCTGCAA-3’ and HPV16 
E6 reverse 5’-AATCCCGAAAAGCAAAGTCAT-3’;) and Jha et al. [8] (HPV18 E6 
forward 5’-CCAGAAACCGTTGAATCCAG-3’ and HPV18 E6 reverse 5’-
GTTGGAGTCGTTCCTGTCGT-3’;), amplifying a 109 bp and a 131 bp specific 
products of HPV16 and HPV18 E6 mRNA, respectively. Novel specific primers for 
the detection of HPV31 E6 gene expression (HPV31 E6 forward 5’-
CCTGCAGAAAGACCTCGGAA-3’ and reverse 5’-
TGGTGTGTCGTCCCTATATACTATTG-3’) were designed giving rise to a 165 bp 
specific amplicon. GAPDH and β-actin were used as our assays endogenous 
reference genes. Specific β-actin, as described in Shi et al. [7] (β-actin forward 5’-
CCCAGATCATGTTTGAGACCT-3’ and β-actin reverse 5’-
AGTCCATCACGATGCCAGT-3’;), and GAPDH (GAPDH forward 5’-
ATGGGGAAGGTGAAGGTCG-3’ and GAPDH reverse 5’-
GGGTCATTGATGGCAACAATATC-3’) primers were synthesized and used for the 
amplification of 105 bp and 107 bp specific products, respectively. 
 The qPCR was performed in the 7500 Real-Time PCR System using the 
sequence detection software (Applied Biosystems, Carlsbad, CA, USA). The 10 µl 
reaction mixture consists of Kapa SYBR® Fast Universal 2X qPCR Master Mix (Kapa 
Biosystems, Inc., Woburn, MA, USA), 300 nM of each qPCR primer and 1.0 µl cDNA 
for HPV16 E6, GAPDH and β-actin reactions, or 1.5 µl cDNA for HPV18 E6 and 
HPV31 E6 reactions. The thermal protocol consists of a 3 min polymerase activation 
step at 95oC, followed by 40 cycles of denaturation at 95oC for 15 sec and the primer 
annealing and extension step at 60oC for 1 min. Melting curve analysis and agarose 
gel electrophoresis were performed following the amplification in order to distinguish 
the accumulation of the specific reaction products from non-specific ones or primer-
dimers. 
 Duplicate reactions were performed for each tested sample and the average 
CT was calculated and evaluated for the analysis. Both GAPDH and β-actin were 
used as our assays endogenous reference genes for normalization purposes. SiHa 
cervix squamous cell carcinoma cell line and HeLa cervix adenocarcinoma cell line 
were used as our assays positive control for HPV16 and HPV18 E6 mRNA, 




The primary and secondary objectives were to evaluate the value of HPV/p16 
status as predictive factor of treatment benefit in terms of PFS and OS respectively, 
in patients who participated in the EORTC 24971/TAX323 phase III clinical trial. 
Additional investigations were proposed in a second stage to evaluate (1) the 
prognostic effect of p16/HPV markers; (2) the predictive and prognostic effect of HPV 
DNA ISH and HPV RNA qPCR. In addition, the same analysis, restricted to 
oropharynx only, was conducted. The following markers were assessed in these 
samples: a. Conventional IHC on TMA for p16 expression status (positive/negative), 
b. PCR and qPCR for HPV DNA (positive/negative), c. ISH for HPV DNA 
(positive/negative), d. qPCR for HPV E6 mRNA (positive/negative). The first two (a. 
and b.) were combined in order to classify patients into two groups: p16 or HPV DNA 
PCR negative and p16 & HPV DNA PCR both positive.  
PFS and OS curves by treatment and marker strata were produced using the 
Kaplan-Meier method. PFS and OS were based on the long-term survival analysis 
produced in 2011 [9]. Statistical significance of predictive effects was assessed 
based on the model used in the primary analysis of the study with the addition of a 
treatment by marker interaction term. This was a multivariate Cox proportional 
hazards model with treatment, marker and treatment by marker interaction effects, 
adjusted for the following covariates: location of primary tumor (oral cavity, 
oropharynx, or hypopharynx), clinical tumor stage (T), regional-node stage (N), and 
WHO score for performance status. For the two initially planned analyses, the 
treatment by marker interaction was tested at a two-sided 5% significance level. The 
estimate of the hazard ratio HR for treatment in each marker strata was provided with 
its 95% confidence interval. For the additional analyses (22 statistical tests), the 
Benjamini-Hochberg method was applied to control the False Discovery Rate (FDR). 
Additional information is provided in supplementary information text. 
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